Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer - Concepedia

Concepedia

Publication | Closed Access

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer

172

Citations

40

References

2003

Year

Christoph Rochlitz, Robert A. Figlin, Patrick Squiban, Marc Salzberg, Miklos Pless, Richard Herrmann, Éric Tartour, Yongxiang Zhao, Nadine Bizouarne, Martine Baudin,

The Journal of Gene Medicine

Abstract

The administration of TG4010 was generally well tolerated in patients with metastatic tumors, and transient disease stabilization was observed in several patients, warranting further clinical studies with the product.

References

	Year	Citations

Page 1